Niclas Eriksson
Statistiker vid Uppsala kliniska forskningscentrum (UCR)
- Telefon:
- 018-611 95 16
- E-post:
- Niclas.Eriksson@ucr.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 38
- Postadress:
- Uppsala Science Park
Dag Hammarskjölds väg 38
751 85 UPPSALA
Ladda ned kontaktuppgifter för Niclas Eriksson vid Uppsala kliniska forskningscentrum (UCR)
Mer information visas för dig som medarbetare om du loggar in.
Publikationer
Senaste publikationer
- Identification of risk factors for adverse drug reactions in a pharmacovigilance database (2024)
- Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls. (2024)
- Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis (2024)
- Whole genome case-control study of central nervous system toxicity due to antimicrobial drugs (2024)
- Identification of risk factors for adverse drug reactions in a pharmacovigilance database (2023)
Alla publikationer
Artiklar
- Identification of risk factors for adverse drug reactions in a pharmacovigilance database (2024)
- Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls. (2024)
- Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis (2024)
- Whole genome case-control study of central nervous system toxicity due to antimicrobial drugs (2024)
- Identification of risk factors for adverse drug reactions in a pharmacovigilance database (2023)
- Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease (2023)
- Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy (2023)
- Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21) (2023)
- Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets (2023)
- Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events (2022)
- Risk of Revision After Arthroplasty Associated withSpecific Gene Loci (2022)
- Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate (2022)
- Similar risk of cancer in patients younger than 55 years with or without a total hip arthroplasty (THA) (2022)
- Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease (2022)
- Serum Neurofilament Light Chain in Patients With Atrial Fibrillation (2022)
- AGPAT1 as a Novel Colonic Biomarker for Discriminating Between Ulcerative Colitis With and Without Primary Sclerosing Cholangitis (2022)
- Novel Biomarkers Detected by Proteomics Predict Death and Cardiovascular Events in Hemodialysis Patients (2022)
- Genetic Landscape of the ACE2 Coronavirus Receptor (2022)
- HLA variants associated with azathioprine-induced pancreatitis in patients with Crohn's disease (2022)
- Association of Variants Near the Bradykinin Receptor B2 Gene With Angioedema in Patients Taking ACE Inhibitors (2021)
- Patient-reported Outcome in Surgically Treated Pelvic Ring Injuries at 5 Years Post-surgery (2021)
- Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate (2021)
- Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19 (2021)
- Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy (2021)
- Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis (2021)
- Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality (2021)
- Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease (2021)
- Osteoprotegerin predicts cardiovascular events in patients treated with haemodialysis (2021)
- Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations (2020)
- Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals (2020)
- No generally increased risk of cancer after total hip arthroplasty performed due to osteoarthritis (2020)
- MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis (2020)
- Association of Factor V Leiden With Subsequent Atherothrombotic Events A GENIUS-CHD Study of Individual Participant Data (2020)
- Exome sequencing reveals common and rare variants in F5 associated with ACE inhibitor and angiotensin receptor blocker-induced angioedema (2020)
- Next-Generation Sequencing of CYP2C19 in Stent Thrombosis (2020)
- Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. (2020)
- Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival (2019)
- Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes (2019)
- Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention (2019)
- A Genome-Wide Association Study of Bisphosphonate-Associated Atypical Femoral Fracture (2019)
- Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes (2019)
- Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events (2019)
- Subsequent Event Risk in Individuals With Established Coronary Heart Disease (2019)
- Novel Cyp2C19 Genetic Variants associated with Stent Thrombosis (2018)
- Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. (2018)
- Genome‐Wide Association Study of Pandemrix‐Induced Narcolepsy in Sweden – A Possible Role for Glial Derived Neurotrophic Factor (GDNF) (2018)
- Whole exome sequencing in individuals with statin-induced myopathy (2017)
- Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough (2017)
- Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease (2017)
- Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose (2016)
- The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals (2016)
- Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range (2016)
- Genetic variants associated with antithyroid drug-induced agranulocytosis (2016)
- Estimating pre-traumatic quality of life in patients with surgically treated acetabular fractures and pelvic ring injuries (2016)
- Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome (2016)
- Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome (2015)
- NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO) (2015)
- Effect of genetic variations on ticagrelor plasma levels and clinical outcomes (2015)
- Association of cyclooxygenase-2 genetic variant with cardiovascular disease (2014)
- Waran doseras bättre efter genanalys (2014)
- Polymorphism of the cystatin C gene in patients with acute coronary syndromes (2014)
- Large-scale association analysis identifies new risk loci for coronary artery disease (2013)
- Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding (2013)
- A Randomized Trial of Genotype-Guided Dosing of Warfarin (2013)
- Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin (2013)
- Prediction of warfarin dose (2012)
- Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy (2012)
- Graft Loss Risk in Renal Transplant Recipients with Metabolic Syndrome (2012)
- Anticoagulation control in Sweden (2011)
- Association of Admission Blood Glucose and Outcome in Patients Treated With Intravenous Thrombolysis (2010)
- Warfarin pharmacogenetics (2010)
- Estimation of the warfarin dose with clinical and pharmacogenetic data (2009)
- Metabolic syndrome and cardiovascular risk in renal transplant recipients (2009)
- A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose (2009)
- The largest prospective warfarin-treated cohort supports genetic forecasting (2009)
- Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) (2008)
- Surgical and long-term mortality in 2634 consecutive patients operated on the proximal thoracic aorta (2007)
- Association of warfarin dose with genes involved in its action and metabolism (2007)
- The Swedish Heart Surgery Register (2006)
- Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing (2005)
- Common VKORC1 and GGCX polymorphisms associated with warfarin dose (2005)
- A two-step proteomic approach identifies candidate biomarker in ulcerative colitis with concomitant primary sclerosing cholangitis.
- Novel biomarkers detected by proteomics predict death and cardiovascular events in hemodialysis patients
- Network-Based Analysis of Protein Interactions among Drugs and Adverse Reactions: Identifying Phenotype-Groupings and Key Genes
Böcker
